Cancer DNA in Blood Helps Personalize Liver Cancer Treatment

They designed personalized assays targeting somatic rearrangements of each tumor to quantify serum ctDNA. Exome sequencing was performed using cell-free DNA paired primary tumor tissue DNA from a patient with recurrent liver cancer after transcatheter arterial chemoembolization (TACE).

The team used a chemiluminescent immunoassay (Fujirebio; Tokyo, Japan) and chemiluminescent enzyme immunoassay (Abbott Laboratories, Abbott Park, IL, USA) to analyze α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), respectively. Thresholds for AFP and DCP abnormalities were defined as 10 ng/mL and 30 mAU/mL, respectively. Cell-free DNA was extracted from 100 μL of preoperative serum by the SMI-TEST (Genome Science Laboratories, Tokyo, Japan). Real-time polymerase chain reaction (PCR) analysis was performed on samples that tested positive in the detection assay and for which serial serum samples were available. PCR was performed using the Mx300P System (Applied Biosystems, Foster City, CA, USA).

The investigators were able to identify 25 common mutations in samples of cell-free DNA, which includes DNA from both normal cells and cancer cells, and DNA from tumors themselves. Furthermore, 83% of mutations identified in the tumor tissues could be detected in the cell-free DNA. They found ctDNA in seven patients and they say that ctDNA has the potential to be a noninvasive way of studying the genetic rearrangements that a cancer has undergone. This information could help doctors provide targeted therapy specific to a patient's cancer. They also demonstrated that the level of serum ctDNA reflected the treatment effect and the progression of hepatocellular carcinoma (HCC). The study was published in the September 2015 issue of the journal Cellular and Molecular Gastroenterology and Hepatology.

Related Links:
Hiroshima University 
Fujirebio 
Abbott Laboratories